

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

NOVO NORDISK A/S,  
Patent Owner

---

Case IPR2023-00723  
Patent 8,129,343

---

**PATENT OWNER'S PRELIMINARY RESPONSE  
UNDER 37 C.F.R. § 42.107**

**LIST OF EXHIBITS**

<b>Exhibit</b>	<b>Description</b>
EX2001	Excerpt of Defendants' Initial Invalidation Contentions, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 1:22-cv-01040-CFC, (D. Del. Oct. 20, 2022)
EX2002	J. Lau, P. Bloch, et al., "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide," <i>Med. Chem.</i> , 58:7370-7380 (2015)
EX2003	U.S. Patent No. 10,335,462
EX2004	B. Furman, N. Pyne, P. Flatt & F. O'Harte, "Targeting B-cell cyclic adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus," <i>J. Pharmacy and Pharmacology</i> , 56:1477-1492 (2004)
EX2005	WO98/32466
EX2006	U.S. Patent No. 6,528,486
EX2007	WO00/69911
EX2008	Excerpt of Plaintiffs' Initial Responses to Defendants' Initial Invalidation Contentions, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 1:22-cv-01040-CFC, (D. Del. Dec. 21, 2022)
EX2009	Declaration of Sayem Osman

**TABLE OF CONTENTS**

I. Introduction.....1

II. Claims Are Directed To A Novel, Non-Obvious Invention.....5

III. Petitioner’s References Identify Thousands of Compounds and Potential Modifications .....8

    A. Knudsen 2004 (EX1010).....8

    B. Knudsen 2001 (EX1011).....9

    C. Knudsen Patent (EX1012).....11

    D. Dong (EX1013) .....13

    E. Bridon (EX1014).....14

IV. Claim Construction.....15

V. §314(a) Discretionary Denial: Ground 3 Fails to Identify “With Particularity” Each Reference and Combination on Which the Challenge is Based, and Its Extraordinary, Prejudicial Impropriety Requires Denial .....15

VI. Grounds 1-2: Petitioner’s Lead Compound Analysis Is Legally Deficient .....18

    A. Petitioner’s Lead Compound Analysis Fails.....19

    B. Even if Liraglutide Were Selected as a Lead, Petitioner Fails to Establish “Motivation To Combine” .....23

        1. Petitioner Ignores The Numerous Types and Locations of Potential Modifications to Liraglutide Other than Those in Semaglutide.....24

        2. Even Focusing on the Types of Modifications Needed to Arrive at Semaglutide, Petitioner Ignores The Numerous Options for Implementing Them.....27

    C. Petitioner Fails To Establish REOS In Creating Semaglutide.....43

        1. Petitioner Fails to Show REOS For Individual Modifications .44

        2. Petitioner Fails to Show REOS For Its Argued Combination of Modifications .....47

VII. Ground 3: Petitioner’s Obvious-To-Try Analysis Fails .....49

VIII. Grounds 1-3: Objective Evidence of Non-Obviousness .....54

    1. The Results Were Unexpected.....54

    2. Long-Felt Need .....56

IX. Institution Should Be Denied Under §325(d).....56

    A. Advanced Bionics Part One .....58

    B. Advanced Bionics Part Two.....64

X. Conclusion .....71

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>10X Genomics, Inc. v. Bio-Rad Labs., Inc.</i> , IPR2021-00133, Pap.11 (May 14, 2021).....	69
<i>Adaptics Ltd. v. Perfect Co.</i> , IPR2018-01596, Pap.20 (Mar. 6, 2019) (informative).....	4, 15, 16, 17, 18
<i>Adidas AG v. Nike, Inc.</i> , 963 F.3d 1355 (Fed. Cir. 2020) .....	34, 37
<i>ADT LLC v. Vivint, Inc.</i> , IPR2022-00634, Pap.7 (Oct. 4, 2022) .....	16, 17
<i>Advanced Bionics, LLC v. MED-EL Elektromedizinische Gerate GmbH</i> , IPR2019-01469, Pap.6 (Feb. 13, 2020) (precedential).....	<i>passim</i>
<i>Agrinomix, LLC v. Mitchell Ellis Prods., Inc.</i> , IPR2017-00525, Pap.8 (June 14, 2017).....	68
<i>Alarm.com, Inc. v. Vivint, Inc.</i> , IPR2022-00728, Pap.6 (Nov. 1, 2022) .....	60
<i>Amgen Inc. v. Sandoz Inc.</i> , 66 F.4th 952 (Fed. Cir. 2023) .....	54
<i>Apple Inc. v. Universal Secure Registry, LLC</i> , IPR2018-00808, Pap.9 (Oct. 9, 2018) .....	49
<i>In re Applied Materials, Inc.</i> , 692 F.3d 1289 (Fed. Cir. 2012) .....	47
<i>Aquestive Therapeutics, Inc. v. Neurelis, Inc.</i> , IPR2019-00451, Pap.8 (Aug. 13, 2019) .....	63
<i>Autel Intelligent Tech. Corp. v. Orange Elec. Co.</i> , IPR2021-01545, Pap.8 (Apr. 8, 2022).....	60

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.